Skip to main content

Reata Pharmaceuticals has been acquired by Biogen. Please visit www.biogen.com for more information.

Site Search
Reata Pharmaceuticals Inc. logo
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window

Nrf2 Activators

©Reata Pharmaceuticals, Inc.
Proprietary Reata Nrf2 activator bound to Keap1
PDB Code 5DAF

  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations

We are developing Nrf2 activators to treat chronic diseases characterized by mitochondrial dysfunction, oxidative stress, and chronic inflammation.

Mitochondria are often called the "powerhouses" of the cell because of their ability to efficiently generate the energy cells need in the form of adenosine triphosphate (ATP). However, mitochondria also play an important role in inflammation. As part of the inflammatory response, cells undergo a "metabolic shift" that reduces ATP production by the mitochondria (1). Instead, mitochondria produce reactive oxygen species (ROS) and other byproducts that amplify inflammation (2-4). This metabolic shift is meant to be a temporary response to infection or injury. Once resolved, it is critical that mitochondrial metabolism returns to its normal state, ROS are neutralized, and inflammatory processes are turned off (5).

References

References

  1. Breda, C. N. S., Davanzo, G. G., Basso, P. J., Saraiva Camara, N. O., and Moraes-Vieira, P. M. M. (2019) Mitochondria as central hub of the immune system. Redox Biol 26, 101255
  2. Banoth, B., and Cassel, S. L. (2018) Mitochondria in innate immune signaling. Transl Res 202, 52-68
  3. Jung, J., Zeng, H., and Horng, T. (2019) Metabolism as a guiding force for immunity. Nat Cell Biol 21, 85-93
  4. West, A. P., Brodsky, I. E., Rahner, C., Woo, D. K., Erdjument-Bromage, H., Tempst, P., Walsh, M. C., Choi, Y., Shadel, G. S., and Ghosh, S. (2011) TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472, 476-480
  5. Gilroy, D., and De Maeyer, R. (2015) New insights into the resolution of inflammation. Semin Immunol 27, 161-168
back to top
Blue Bonnets
Reata Pharmaceuticals Inc. logo

Intended for US residents only.

  • Sitemap
  • Legal Message
  • Privacy Notice
  • Social Media Disclosure
  • Contact Us
Powered By Q4 Inc. 5.104.0.1 (opens in new window)

© Reata Pharmaceuticals, Inc., All Rights Reserved. | US-NON-2100018 | 09/2023

Stay Connected Mobile

  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window